Build status - In Progress

Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)

Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study)
Recruiting
12 years - 99 years
All
Phase 1
10 participants needed
1 Location

Brief description of study

The primary purpose of this study is to assess the safety and tolerability of an Investigational drug in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Solid Tumor
  • Age: 12 years - 99 years
  • Gender: All

Male or female and ≥12 years-of-age, advanced or metastatic resistant or refractory solid tumors.

Updated on 04 Aug 2024. Study ID: 849282

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center